Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederema.europa.eu
New medicines: human
Get the latest updates from New medicines: human directly as they happen.
Follow now 411 followers
Latest posts
Last updated 17 days ago
Human medicines European public assessment report (EPAR): Stoboclo, denosumab, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Stoboclo, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Eydenzelt, aflibercept, Status: Opinion
Human medicines European public assessment report (EPAR): Emcitate, tiratricol, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Emcitate, tiratricol, Status: Opinion
Human medicines European public assessment report (EPAR): Rytelo, imetelstat sodium, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Rytelo, imetelstat sodium, Status: Opinion
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, Status: Opinion
Human medicines European public assessment report (EPAR): Paxneury, guanfacine, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Paxneury, guanfacine, Status: Opinion
Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Status: Opinion
Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Status: Opinion
Human medicines European public assessment report (EPAR): Andembry, garadacimab, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Andembry, garadacimab, Status: Opinion
Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Tuzulby, methylphenidate hydrochloride, Status: Opinion
17 days ago
Human medicines European public assessment report (EPAR): Tuzulby, methylphenidate hydrochloride, Status: Opinion